A complete application in a minute
Tailored resume and cover letter, ready to send.
Oxford BioMedica Limited is seeking a Project/Programme Manager to join our Commercial team on a 12-month fixed-term contract. You will manage the relationship between OXB and its clients to ensure projects are delivered on time and within budget to the required quality, enabling long-term alliances and supporting our mission in cell and gene therapy.
OXB is a global contract development and manufacturing organisation (CDMO) dedicated to enabling life-changing therapies.
Scientific Degree or PhD.
At OXB, our people are at the heart of everything we do. We're on a mission to enable life-changing therapies to reach patients around the world-and we're looking for passionate individuals who embody our core values every day: Responsible, Responsive, Resilient, and Respectful.
We're currently recruiting for a Project/Programme Manager to join our Commercial team on a 12-month fixed-term contract. In this role, you will be managing the relationship between OXB and its Clients and ensure projects are delivered on time and within budget to the required quality to ensure successful long-term alliances, playing a key role in advancing our mission and making a real difference., OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, OXB has 30 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB's world-class capabilities range from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. OXB offers a vast number of technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the TetraVecta system), a dual-plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines. OXB, a FTSE250 and FTSE4Good constituent, is headquartered in Oxford, UK. It has development and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France, Bedford MA, and Durham NC, US.
Ready to Make a Difference?